CN103285397A - External compound medicine for treating acne - Google Patents
External compound medicine for treating acne Download PDFInfo
- Publication number
- CN103285397A CN103285397A CN 201210069769 CN201210069769A CN103285397A CN 103285397 A CN103285397 A CN 103285397A CN 201210069769 CN201210069769 CN 201210069769 CN 201210069769 A CN201210069769 A CN 201210069769A CN 103285397 A CN103285397 A CN 103285397A
- Authority
- CN
- China
- Prior art keywords
- acne
- compound medicine
- medicine
- external compound
- externally used
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to an external compound medicine for treating acne. The external compound medicine is characterized in that a substrate carrier of the external compound medicine contains the following active ingredients, such as non-steroidal anti-inflammatory agents, cimetidine and antibacterial. The external compound medicine has the advantages that the three active ingredients simultaneously act on a plurality of links (anti-inflammation, antibiosis and reduction of sebum secretion) in the acne pathological process. Thus, the curative effect on the acne, especially inflammatory acne is improved; the external compound medicine is high in safety, and free of thrill and anaphylaxis; the contained active ingredients are cheap and available; and the finished medicament is certain to be accepted by wide patients with acnes.
Description
Technical field:
The present invention relates to a kind of externally used compound medicine for the treatment of acne.
Background technology
Acne is commonly called as acne, comedo etc., is the sebaceous gland chronic disease, and sickness rate is very high in youth of both sexes, causes certain tired brain and pressure to patient.
Acne can be divided into polytype, generally is divided into inflammatory and non-inflammatory acne two classes, and is the highest with the acne sickness rate.
The acne pathogenic factors has multiple, and its pathological process relates generally to four aspects: 1. the androgen level raises or raises relatively in the body, causes smegma hyperfunction; 2. too much sebum is beneficial to invasion and attack and the breeding of microorganism; 3. the pilosebaceous duct dyskeratosis causes acne to form; 4. the startup of inflammation causes the inflammation that occurrence degree does not wait around the hair follicle.
Medicine is the main means for the treatment of acne, can oral or external, and for reducing adverse effect based on external.Acne is mainly used antibiotic and anti-inflammation drugs; Mainly use the dissolving medicine for treating comedo for non-inflammatory acne.
At present mostly be the folk prescription that contains antimicrobial drug in the external used medicine for the treatment of acne, act on singlely, curative effect is not ideal enough; Antiinflammatory is the important means for the treatment of acne, though the corticosteroids medicine has powerful antiinflammatory action, and can the apply telangiectasis of medicine position, erythema, state of an illness knock-on etc. after the drug withdrawal is so be rarely used in remedy of acne; Though the medicine of dissolving acne such as tretinoin and derivant thereof are obvious to the non-inflammatory acne curative effect, have the big shortcoming of teratogenesis or zest, are only applicable to severe acne; Though also have many compound external-use preparations, all have such or such problem.
Summary of the invention
The objective of the invention is to: a kind of acne for the treatment of is provided, especially acne is had the new external used medicine of good therapeutical effect.
The object of the present invention is achieved like this: in a kind of externally used compound medicine for the treatment of acne, contain the active component that disturbs a plurality of pathology links of acne simultaneously, to improve its curative effect of medication.These active component comprise antiandrogen medicine, anti-inflammatory agent and antimicrobial drug.
The antiandrogen medicine is selected the cimetidine in the H2 receptor blocking agent for use.This product is the medicine for the treatment of stomach, duodenal ulcer disease, finds that later on it has the antiandrogen effect, can stop testosterone and hair follicle receptors bind, thereby suppresses the secretion of sebaceous gland.Add this composition in this compound medicine, play the effect of effecting a permanent cure.
Antibacterials are selected for use has strong the inhibition or the medicine of killing action to the relevant The main pathogenic fungi of acne morbidity such as propanoic acid Propiobacterium, example hydrochloric acid clindamycin, clindamycin phosphate, metronidazole, tinidazole, ornidazole etc., thus alleviate or eliminate the morbidity the infection link.
We have expected NSAID (non-steroidal anti-inflammatory drug) anti-inflammatory treatment, such medicine is brought into play antiinflammatory action by the generation that the inhibition epoxidase reduces the inflammatory mediator prostaglandin, all effective to acute and chronic inflammation, especially granulomatous inhibition is had more significance to remedy of acne.We, are surprised to find in clinical treatment observation after adding the NSAID (non-steroidal anti-inflammatory drug) diclofenac sodium in this compound medicine, and skin lesion begins to disappear in many after medication 1～3 days, and total effective rate obviously improves, and presents quick-acting, efficient characteristics.Infer its reason, except the antiinflammatory action of diclofenac sodium itself, after the hyperemia of skin lesion position, the edema extinction, also be conducive to other drug to the infiltration of deep tissue, thereby curative effect improves.In addition, diclofenac sodium and cimetidine can be brought into play synergism aspect antiinflammatory because the latter can part to the vasodilation due to the antihistamine with ooze out.
From the above mentioned, the invention has the advantages that: the active component that contains cimetidine, antimicrobial drug and three kinds of treatments of NSAID (non-steroidal anti-inflammatory drug) acne in this compound preparation, bring into play antiinflammatory, antibiotic and reduce effect such as sebum secretion simultaneously, so that therapeutical effect more comprehensively, deeply, curative effect is more satisfied; This compound preparation nonirritant and anaphylaxis; Because material medicine is easy to get, and cheap, made finished medicines is bound to be accepted by vast patients with acne.
The specific embodiment:
Below non-limitingly exemplify part example involved in the present invention.
Embodiment 1:
The effective active composition of present embodiment adopts diclofenac sodium 0.5%, Clindamycin Hydrochloride 1%, and cimetidine 1%, medium carrier adopts isopropyl alcohol, propylene glycol and distilled water, makes liniment.
Embodiment 2
The effective active composition of present embodiment adopts diclofenac sodium 1%, clindamycin phosphate 1%, and cimetidine 2%, substrate is carried and is done to adopt hexadecanol, vaseline, liquid paraffin, glyceryl monostearate, glycerol, triethanolamine and distillation, makes ointment.
Embodiment 3:
The effective active composition of present embodiment adopts diclofenac sodium 1%, ornidazole 2%, and cimetidine 2%, medium carrier adopts carbomer, isopropyl alcohol, propylene glycol, disodium edetate and distilled water, makes gel.
We have carried out preliminary observation of curative effect to the students (about 80 people) that part is suffered from acne with the liniment of this compound external-use medicine, are reference substance with Cuo health king (clindamycin metronidazole liniment, Kuning Dianhong Pharmaceutical Co., Ltd. produces).Each coating 0.5～2ml, every day 2 times, 4 weeks of continuous use.The result: the test group effective percentage is 91.1%; The matched group effective percentage is 73.2%.Show this liniment have quick-acting, efficient, have no adverse reaction, do not have greasy feeling and advantage such as easy to use.
Claims (5)
1. an externally used compound medicine for the treatment of acne is characterized in that: be by NSAID (non-steroidal anti-inflammatory drug), H in this compound external-use drug matrices carrier
2Receptor blocking agent, antimicrobial drug three class effective actives become branch to form.
2. according to the externally used compound medicine of the described treatment acne of claim 1, it is characterized in that: contain NSAID (non-steroidal anti-inflammatory drug), its content (percentage by weight) is 0.5%～2%.
3. according to the externally used compound medicine of the described treatment acne of claim 1, it is characterized in that: contain H
2Receptor blocking agent, should selecting for use wherein, cimetidine is good.Its content (percentage by weight) is 1%～2%.
4. according to the externally used compound medicine of the described treatment acne of claim 1, it is characterized in that: contain antimicrobial drug: its content (percentage by weight) is 0.1%～5%.
5. according to the externally used compound medicine of the described treatment acne of claim 1, it is characterized in that: the effective active composition that it contains forms emulsifiable paste or gel or liniment or liniment with after medium carrier mixes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210069769 CN103285397A (en) | 2012-03-03 | 2012-03-03 | External compound medicine for treating acne |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210069769 CN103285397A (en) | 2012-03-03 | 2012-03-03 | External compound medicine for treating acne |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103285397A true CN103285397A (en) | 2013-09-11 |
Family
ID=49087281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210069769 Withdrawn CN103285397A (en) | 2012-03-03 | 2012-03-03 | External compound medicine for treating acne |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103285397A (en) |
-
2012
- 2012-03-03 CN CN 201210069769 patent/CN103285397A/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9056086B2 (en) | Pharmaceutical compositions comprising DGLA, 15-HEPE, and/or 15-HETrE and methods of use thereof | |
| KR101018352B1 (en) | Composition of comprising bee-venoms for treating acne | |
| JP2002512971A (en) | Topical substance mixture containing olive oil and honey | |
| US20150094370A1 (en) | Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same | |
| MXPA06008988A (en) | Topical antiacne preparations containing retinoid (tazarotene or adapalene), antibiotic (clindamycin phosphate) and/or keratolytic (miscrosponged benzoyl peroxide). | |
| RU2007118663A (en) | METHOD FOR ADAPALENE SUPPORT FOR SUPPORT THERAPY OF AN ACID CRUSH | |
| KR20110074513A (en) | Topical treatment of skin infection | |
| KR20050089740A (en) | Topical formulation for treatment of rosacea | |
| EP1152748B1 (en) | Method and composition for treating acne | |
| JP4243353B2 (en) | Zinc salt of conjugated linoleic acid for the treatment of skin diseases | |
| US20140199413A1 (en) | Melatonin and an antimicrobial or antibacterial agent for the treatment of acne | |
| JP2015081244A (en) | Acne treating pharmaceutical composition | |
| US20200030398A1 (en) | Skin care composition | |
| EP2114392A1 (en) | Use of adapalene and benzoyl peroxide for the long term treatment of acne vulgaris | |
| CN103285397A (en) | External compound medicine for treating acne | |
| US20080287373A1 (en) | Topical skin treating kits | |
| CN104434946A (en) | Compound drug for external use for treating acne | |
| WO2010038234A1 (en) | Combination product of spironolactone and doxycycline | |
| CN101766731B (en) | Tea polyphenol acne resistant external preparation | |
| CA2540859A1 (en) | Topical compositions comprising telmesteine for treating dermatological disorders | |
| CN112791093A (en) | Transdermal drug delivery composition for treating acne and preparation method thereof | |
| CN1528327A (en) | Complex external medicine speical for acne and preparing method thereof | |
| EP2588095A1 (en) | Composition for the treatment of acne vulgaris | |
| CN109498615B (en) | Transdermal drug delivery preparation for treating primary trigeminal neuralgia and application thereof | |
| CN106377484A (en) | Preparation method of pharmaceutical mask |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C04 | Withdrawal of patent application after publication (patent law 2001) | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20130911 |